-
1
-
-
42649145828
-
Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): a literature review
-
Gupta K., Miller J.D., Li J.Z., et al. Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): a literature review. Cancer Treat Rev 2008, 34:193-205.
-
(2008)
Cancer Treat Rev
, vol.34
, pp. 193-205
-
-
Gupta, K.1
Miller, J.D.2
Li, J.Z.3
-
2
-
-
68549096316
-
Targeted inhibition of mammalian target of rapamycin for the treatment of advanced renal cell carcinoma
-
Kapoor A., Figlin R.A. Targeted inhibition of mammalian target of rapamycin for the treatment of advanced renal cell carcinoma. Cancer 2009, 115:3618-3630.
-
(2009)
Cancer
, vol.115
, pp. 3618-3630
-
-
Kapoor, A.1
Figlin, R.A.2
-
3
-
-
33846224397
-
The follow-up management of non-metastatic renal cell carcinoma: definition of a surveillance protocol
-
Antonelli A., Cozzoli A., Zani D., et al. The follow-up management of non-metastatic renal cell carcinoma: definition of a surveillance protocol. BJU Int 2007, 99:296-300.
-
(2007)
BJU Int
, vol.99
, pp. 296-300
-
-
Antonelli, A.1
Cozzoli, A.2
Zani, D.3
-
4
-
-
33846181370
-
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma
-
Motzer R.J., Hutson T.E., Tomczak P., et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007, 356:115-124.
-
(2007)
N Engl J Med
, vol.356
, pp. 115-124
-
-
Motzer, R.J.1
Hutson, T.E.2
Tomczak, P.3
-
5
-
-
33846148701
-
For the TARGET Study Group. Sorafenib in advanced clear-cell renal-cell carcinoma
-
Escudier B., Eisen T., Stadler W.M., et al. For the TARGET Study Group. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007, 356:125-134.
-
(2007)
N Engl J Med
, vol.356
, pp. 125-134
-
-
Escudier, B.1
Eisen, T.2
Stadler, W.M.3
-
6
-
-
37349080670
-
For the AVOREN Trial Investigators. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial
-
Escudier B., Pluzanska A., Koralewski P., et al. For the AVOREN Trial Investigators. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 2007, 370:2103-2111.
-
(2007)
Lancet
, vol.370
, pp. 2103-2111
-
-
Escudier, B.1
Pluzanska, A.2
Koralewski, P.3
-
7
-
-
77949890945
-
Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial
-
Sternberg C.N., Davis I.D., Mardiak J., et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 2010, 28:1061-1068.
-
(2010)
J Clin Oncol
, vol.28
, pp. 1061-1068
-
-
Sternberg, C.N.1
Davis, I.D.2
Mardiak, J.3
-
8
-
-
34249779568
-
Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma
-
Hudes G., Carducci M., Tomczak P., et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007, 356:2271-2281.
-
(2007)
N Engl J Med
, vol.356
, pp. 2271-2281
-
-
Hudes, G.1
Carducci, M.2
Tomczak, P.3
-
9
-
-
77956227464
-
Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors
-
Motzer R.J., Escudier B., Oudard S., et al. Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer 2010, 116:4256-4265.
-
(2010)
Cancer
, vol.116
, pp. 4256-4265
-
-
Motzer, R.J.1
Escudier, B.2
Oudard, S.3
-
10
-
-
0034682783
-
Hypoxia inducible factor-alpha binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein
-
Cockman M.E., Masson N., Mole D.R., et al. Hypoxia inducible factor-alpha binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein. J Biol Chem 2000, 275:25733-25741.
-
(2000)
J Biol Chem
, vol.275
, pp. 25733-25741
-
-
Cockman, M.E.1
Masson, N.2
Mole, D.R.3
-
11
-
-
4644363095
-
The von Hippel-Lindau tumor suppressor gene and kidney cancer
-
Kaelin W.G. The von Hippel-Lindau tumor suppressor gene and kidney cancer. Clin Cancer Res 2004, 10:6290S-6295S.
-
(2004)
Clin Cancer Res
, vol.10
-
-
Kaelin, W.G.1
-
12
-
-
16644373473
-
Role of VHL gene mutation in human cancer
-
Kim W.Y., Kaelin W.G. Role of VHL gene mutation in human cancer. J Clin Oncol 2004, 22:4991-5004.
-
(2004)
J Clin Oncol
, vol.22
, pp. 4991-5004
-
-
Kim, W.Y.1
Kaelin, W.G.2
-
13
-
-
77956511880
-
The mTOR pathway: a new target in cancer therapy
-
Ciuffreda L., Di S.C., Incani U.C., Milella M. The mTOR pathway: a new target in cancer therapy. Curr Cancer Drug Targets 2010, 10:484-495.
-
(2010)
Curr Cancer Drug Targets
, vol.10
, pp. 484-495
-
-
Ciuffreda, L.1
Di, S.C.2
Incani, U.C.3
Milella, M.4
-
14
-
-
61349116156
-
EORTC-GU group expert opinion on metastatic renal cell cancer
-
de Reijke T.M., Bellmunt J., van Poppel H., et al. EORTC-GU group expert opinion on metastatic renal cell cancer. Eur J Cancer 2009, 45:765-773.
-
(2009)
Eur J Cancer
, vol.45
, pp. 765-773
-
-
de Reijke, T.M.1
Bellmunt, J.2
van Poppel, H.3
-
15
-
-
77954326508
-
On behalf of the ESMO Guidelines Working Group. Renal cell carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up
-
Escudier B., Kataja V. On behalf of the ESMO Guidelines Working Group. Renal cell carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2009, 21(Suppl. 5):v137-v139.
-
(2009)
Ann Oncol
, vol.21
, Issue.SUPPL. 5
-
-
Escudier, B.1
Kataja, V.2
-
16
-
-
77955493600
-
EAU guidelines on renal cell carcinoma: the 2010 update
-
Ljungberg B., Cowan N., Hanbury D.C., et al. EAU guidelines on renal cell carcinoma: the 2010 update. Eur Urol 2010, 58:398-406.
-
(2010)
Eur Urol
, vol.58
, pp. 398-406
-
-
Ljungberg, B.1
Cowan, N.2
Hanbury, D.C.3
-
17
-
-
84881544648
-
-
Pfizer Inc. Torisel®, Summary of product characteristics, November 2010.
-
Pfizer Inc. Torisel®, Summary of product characteristics, November 2010.
-
-
-
-
18
-
-
84881543936
-
-
Novartis Pharmaceuticals UK Ltd. Afinitor® (everolimus), Summary of product characteristics, May 2010. Available from:
-
Novartis Pharmaceuticals UK Ltd. Afinitor® (everolimus), Summary of product characteristics, May 2010. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/001038/WC500022814.pdf.
-
-
-
-
19
-
-
33746637660
-
Current development of mTOR inhibitors as anticancer agents
-
Faivre S., Kroemer G., Raymond E. Current development of mTOR inhibitors as anticancer agents. Nat Rev Drug Discov 2006, 5:671-688.
-
(2006)
Nat Rev Drug Discov
, vol.5
, pp. 671-688
-
-
Faivre, S.1
Kroemer, G.2
Raymond, E.3
-
20
-
-
0028950217
-
Isolation of a protein target of the FKBP12-rapamycin complex in mammalian cells
-
Sabers C.J., Martin M.M., Brunn G.J., et al. Isolation of a protein target of the FKBP12-rapamycin complex in mammalian cells. J Biol Chem 1995, 270:815-822.
-
(1995)
J Biol Chem
, vol.270
, pp. 815-822
-
-
Sabers, C.J.1
Martin, M.M.2
Brunn, G.J.3
-
21
-
-
72849150434
-
Targeting tumorigenesis: development and use of mTOR inhibitors in cancer therapy
-
Yuan R., Kay A., Berg W.J., Lebwohl D. Targeting tumorigenesis: development and use of mTOR inhibitors in cancer therapy. J Hematol Oncol 2009, 2:45.
-
(2009)
J Hematol Oncol
, vol.2
, pp. 45
-
-
Yuan, R.1
Kay, A.2
Berg, W.J.3
Lebwohl, D.4
-
22
-
-
84881545414
-
-
Cayman Chemical Company 2012. Available from: Accessed 11 September, 2012.
-
Cayman Chemical Company 2012. Available from: Accessed 11 September, 2012. http://www.caymanchem.com/app/template/Product.vm/catalog/13346.
-
-
-
-
23
-
-
0032930567
-
Absorption and intestinal metabolism of SDZ-RAD and rapamycin in rats
-
Crowe A., Bruelisauer A., Duerr L., et al. Absorption and intestinal metabolism of SDZ-RAD and rapamycin in rats. Drug Metab Dispos 1999, 27:627-632.
-
(1999)
Drug Metab Dispos
, vol.27
, pp. 627-632
-
-
Crowe, A.1
Bruelisauer, A.2
Duerr, L.3
-
24
-
-
34250619165
-
The mammalian target of rapamycin signaling pathway: twists and turns in the road to cancer therapy
-
Abraham R.T., Gibbons J.J. The mammalian target of rapamycin signaling pathway: twists and turns in the road to cancer therapy. Clin Cancer Res 2007, 13:3109-3114.
-
(2007)
Clin Cancer Res
, vol.13
, pp. 3109-3114
-
-
Abraham, R.T.1
Gibbons, J.J.2
-
25
-
-
9144233506
-
Antitumor efficacy of intermittent treatment schedules with the rapamycin derivative RAD001 correlates with prolonged inactivation of ribosomal protein S6 kinase 1 in peripheral blood mononuclear cells
-
Boulay A., Zumstein-Mecker S., Stephan C., et al. Antitumor efficacy of intermittent treatment schedules with the rapamycin derivative RAD001 correlates with prolonged inactivation of ribosomal protein S6 kinase 1 in peripheral blood mononuclear cells. Cancer Res 2004, 54:252-261.
-
(2004)
Cancer Res
, vol.54
, pp. 252-261
-
-
Boulay, A.1
Zumstein-Mecker, S.2
Stephan, C.3
-
26
-
-
45149094232
-
Identifying optimal biologic doses of everolimus (RAD001) in patients with cancer based on the modelling of preclinical and clinical pharmacokinetic and pharmacodynamic data
-
Tanaka C., O'Reilly T., Kovarik J.M., et al. Identifying optimal biologic doses of everolimus (RAD001) in patients with cancer based on the modelling of preclinical and clinical pharmacokinetic and pharmacodynamic data. J Clin Oncol 2008, 26:1596-1602.
-
(2008)
J Clin Oncol
, vol.26
, pp. 1596-1602
-
-
Tanaka, C.1
O'Reilly, T.2
Kovarik, J.M.3
-
27
-
-
84881547402
-
mTOR inhibition following a single intravenous infusion of temsirolimus in healthy individuals
-
Presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, San Francisco, CA, USA, 22-27 October 2007.
-
Boni J, Burns J, Hug B, Sonnichsen D. mTOR inhibition following a single intravenous infusion of temsirolimus in healthy individuals. Presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, San Francisco, CA, USA, 22-27 October 2007.
-
-
-
Boni, J.1
Burns, J.2
Hug, B.3
Sonnichsen, D.4
-
28
-
-
0041662261
-
Pharmacodynamic evaluation of CCI-779, an inhibitor of mTOR, in cancer patients
-
Peralba J.M., DeGraffenried L., Friedrichs W., et al. Pharmacodynamic evaluation of CCI-779, an inhibitor of mTOR, in cancer patients. Clin Cancer Res 2003, 9:2887-2892.
-
(2003)
Clin Cancer Res
, vol.9
, pp. 2887-2892
-
-
Peralba, J.M.1
DeGraffenried, L.2
Friedrichs, W.3
-
29
-
-
35348858663
-
Potential histologic and molecular predictors of response to temsirolimus in patients with advanced renal cell carcinoma
-
Cho D., Signoretti S., Dabora S., et al. Potential histologic and molecular predictors of response to temsirolimus in patients with advanced renal cell carcinoma. Clin Genitourin Cancer 2007, 5:379-385.
-
(2007)
Clin Genitourin Cancer
, vol.5
, pp. 379-385
-
-
Cho, D.1
Signoretti, S.2
Dabora, S.3
-
30
-
-
84881545835
-
Fasting glucose and triglycerides as biomarkers of mTOR inhibition, evidence of a categorical response
-
Presented at the 46th Annual Meeting of the American Society of Clinical Oncology, Chicago, IL, USA, 4-8 June 2010 (Abstract 3091).
-
Nallari AS, Karrison T, Rosner GL, et al. Fasting glucose and triglycerides as biomarkers of mTOR inhibition, evidence of a categorical response. Presented at the 46th Annual Meeting of the American Society of Clinical Oncology, Chicago, IL, USA, 4-8 June 2010 (Abstract 3091).
-
-
-
Nallari, A.S.1
Karrison, T.2
Rosner, G.L.3
-
31
-
-
84861768887
-
Increase in cholesterol predicts survival advantage in renal cell carcinoma patients treated with temsirolimus
-
Lee C.K., Marschner I., Simes J., et al. Increase in cholesterol predicts survival advantage in renal cell carcinoma patients treated with temsirolimus. Clin Cancer Res 2012, 18:3188-3196.
-
(2012)
Clin Cancer Res
, vol.18
, pp. 3188-3196
-
-
Lee, C.K.1
Marschner, I.2
Simes, J.3
-
32
-
-
1542398693
-
Randomized phase II study of multiple dose levels of CCI-779, a mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma
-
Atkins M.B., Hidalgo M., Stadler W.M. Randomized phase II study of multiple dose levels of CCI-779, a mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol 2004, 22:909-918.
-
(2004)
J Clin Oncol
, vol.22
, pp. 909-918
-
-
Atkins, M.B.1
Hidalgo, M.2
Stadler, W.M.3
-
33
-
-
72049114956
-
Intravenous temsirolimus in cancer patients: clinical pharmacology and dosing considerations
-
Boni J.P., Hug B., Leister C., Sonnichsen D. Intravenous temsirolimus in cancer patients: clinical pharmacology and dosing considerations. Semin Oncol 2009, 36(Suppl. 3):S18-S25.
-
(2009)
Semin Oncol
, vol.36
, Issue.SUPPL. 3
-
-
Boni, J.P.1
Hug, B.2
Leister, C.3
Sonnichsen, D.4
-
34
-
-
43249086546
-
Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors
-
O'Donnell A., Faivre S., Burris H.A., et al. Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors. J Clin Oncol 2008, 26:1588-1595.
-
(2008)
J Clin Oncol
, vol.26
, pp. 1588-1595
-
-
O'Donnell, A.1
Faivre, S.2
Burris, H.A.3
-
36
-
-
43249131245
-
Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors
-
Tabernero J., Rojo F., Calvo E., et al. Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors. J Clin Oncol 2008, 26:1603-1610.
-
(2008)
J Clin Oncol
, vol.26
, pp. 1603-1610
-
-
Tabernero, J.1
Rojo, F.2
Calvo, E.3
-
37
-
-
0034746371
-
Longitudinal assessment of everolimus in de novo renal transplant recipients over the first post-transplant year: pharmacokinetics, exposure-response relationships, and influence on cyclosporine
-
Kovarik J.M., Kahan B.D., Kaplan B., et al. Longitudinal assessment of everolimus in de novo renal transplant recipients over the first post-transplant year: pharmacokinetics, exposure-response relationships, and influence on cyclosporine. Clin Pharmacol Ther 2001, 69:48-56.
-
(2001)
Clin Pharmacol Ther
, vol.69
, pp. 48-56
-
-
Kovarik, J.M.1
Kahan, B.D.2
Kaplan, B.3
-
39
-
-
0036151699
-
Effect of food on everolimus absorption: quantification in healthy subjects and a confirmatory screening in patients with renal transplants
-
Kovarik J.M., Hartmann S., Figueiredo J., et al. Effect of food on everolimus absorption: quantification in healthy subjects and a confirmatory screening in patients with renal transplants. Pharmacotherapy 2002, 22:154-159.
-
(2002)
Pharmacotherapy
, vol.22
, pp. 154-159
-
-
Kovarik, J.M.1
Hartmann, S.2
Figueiredo, J.3
-
40
-
-
78650971226
-
Inhibitors of mTOR
-
Klumpen H.J., Beijnen J.H., Gurney H., Schellens J.H. Inhibitors of mTOR. Oncologist 2010, 15:1262-1269.
-
(2010)
Oncologist
, vol.15
, pp. 1262-1269
-
-
Klumpen, H.J.1
Beijnen, J.H.2
Gurney, H.3
Schellens, J.H.4
-
41
-
-
35448978367
-
Pharmacokinetic profile of temsirolimus with concomitant administration of cytochrome p450-inducing medications
-
Boni J., Leister C., Burns J., et al. Pharmacokinetic profile of temsirolimus with concomitant administration of cytochrome p450-inducing medications. J Clin Pharmacol 2007, 47:1430-1439.
-
(2007)
J Clin Pharmacol
, vol.47
, pp. 1430-1439
-
-
Boni, J.1
Leister, C.2
Burns, J.3
-
42
-
-
2942735384
-
Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer
-
Raymond E., Alexandre J., Faivre S., et al. Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer. J Clin Oncol 2004, 22:2336-2347.
-
(2004)
J Clin Oncol
, vol.22
, pp. 2336-2347
-
-
Raymond, E.1
Alexandre, J.2
Faivre, S.3
-
43
-
-
44349099754
-
Differential effects of ketoconazole on exposure to temsirolimus following intravenous infusion of temsirolimus
-
Boni J.P., Leister C., Burns J., Hug B. Differential effects of ketoconazole on exposure to temsirolimus following intravenous infusion of temsirolimus. Br J Cancer 2008, 98:1797-1802.
-
(2008)
Br J Cancer
, vol.98
, pp. 1797-1802
-
-
Boni, J.P.1
Leister, C.2
Burns, J.3
Hug, B.4
-
44
-
-
0033753435
-
Induction of P-glycoprotein by rifampin increases intestinal secretion of talinolol in human beings: a new type of drug/drug interaction
-
Westphal K., Weinbrenner A., Zschiesche M., et al. Induction of P-glycoprotein by rifampin increases intestinal secretion of talinolol in human beings: a new type of drug/drug interaction. Clin Pharmacol Ther 2000, 68:345-355.
-
(2000)
Clin Pharmacol Ther
, vol.68
, pp. 345-355
-
-
Westphal, K.1
Weinbrenner, A.2
Zschiesche, M.3
-
45
-
-
0036014062
-
Effect of rifampin on apparent clearance of everolimus
-
Kovarik J.M., Hartmann S., Figueiredo J., et al. Effect of rifampin on apparent clearance of everolimus. Ann Pharmacother 2002, 36:981-985.
-
(2002)
Ann Pharmacother
, vol.36
, pp. 981-985
-
-
Kovarik, J.M.1
Hartmann, S.2
Figueiredo, J.3
-
46
-
-
17644399505
-
Blood concentrations of everolimus are markedly increased by ketoconazole
-
Kovarik J.M., Beyer D., Bizot M.N., et al. Blood concentrations of everolimus are markedly increased by ketoconazole. J Clin Pharmacol 2005, 45:514-518.
-
(2005)
J Clin Pharmacol
, vol.45
, pp. 514-518
-
-
Kovarik, J.M.1
Beyer, D.2
Bizot, M.N.3
-
47
-
-
84881557122
-
-
EMEA. European Public Assessment Report: Temsirolimus Scientific Discussion. Available from: [accessed 11.09.12]
-
EMEA. European Public Assessment Report: Temsirolimus Scientific Discussion. Available from: [accessed 11.09.12]. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Scientific_Discussion/human/000799/WC500039915.pdf.
-
-
-
-
48
-
-
11344271046
-
Population pharmacokinetics of CCI-779: correlations to safety and pharmacogenomic responses in patients with advanced renal cancer
-
Boni J.P., Leister C., Bender G., et al. Population pharmacokinetics of CCI-779: correlations to safety and pharmacogenomic responses in patients with advanced renal cancer. Clin Pharmacol Ther 2005, 77:76-89.
-
(2005)
Clin Pharmacol Ther
, vol.77
, pp. 76-89
-
-
Boni, J.P.1
Leister, C.2
Bender, G.3
-
49
-
-
0031017851
-
Patient preferences for oral versus intravenous palliative chemotherapy
-
Liu G., Franssen E., Fitch M.I., Warner E. Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol 1997, 15:110-115.
-
(1997)
J Clin Oncol
, vol.15
, pp. 110-115
-
-
Liu, G.1
Franssen, E.2
Fitch, M.I.3
Warner, E.4
-
50
-
-
0036901669
-
Interaction of immunosuppressive agents rapamycin and its analogue SDZ-RAD with endothelial P-gp
-
Laplante A., Demeule M., Murphy G.F., Béliveau R. Interaction of immunosuppressive agents rapamycin and its analogue SDZ-RAD with endothelial P-gp. Transplant Proc 2002, 34:3393-3395.
-
(2002)
Transplant Proc
, vol.34
, pp. 3393-3395
-
-
Laplante, A.1
Demeule, M.2
Murphy, G.F.3
Béliveau, R.4
-
51
-
-
26444602978
-
Pharmacokinetic interaction between verapamil and everolimus in healthy subjects
-
Kovarik J.M., Beyer D., Bizot M.N., et al. Pharmacokinetic interaction between verapamil and everolimus in healthy subjects. Br J Clin Pharmacol 2005, 60:434-437.
-
(2005)
Br J Clin Pharmacol
, vol.60
, pp. 434-437
-
-
Kovarik, J.M.1
Beyer, D.2
Bizot, M.N.3
-
52
-
-
32844467779
-
Biochemical monitoring of mTOR inhibitor-based immunosuppression following kidney transplantation: a novel approach for tailored immunosuppressive therapy
-
Hartmann B., Schmid G., Graeb C., et al. Biochemical monitoring of mTOR inhibitor-based immunosuppression following kidney transplantation: a novel approach for tailored immunosuppressive therapy. Kidney Int 2005, 68:2593-2598.
-
(2005)
Kidney Int
, vol.68
, pp. 2593-2598
-
-
Hartmann, B.1
Schmid, G.2
Graeb, C.3
-
53
-
-
42349113247
-
A new pharmacologic action of CCI-779 involves FKBP12-independent inhibition of mTOR kinase activity and profound repression of global protein synthesis
-
Shor B., Zhang W.G., Toral-Barza L., et al. A new pharmacologic action of CCI-779 involves FKBP12-independent inhibition of mTOR kinase activity and profound repression of global protein synthesis. Cancer Res 2008, 68:2934-2943.
-
(2008)
Cancer Res
, vol.68
, pp. 2934-2943
-
-
Shor, B.1
Zhang, W.G.2
Toral-Barza, L.3
-
54
-
-
33646023695
-
Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB
-
Sarbassov D.D., Ali S.M., Sengupta S., et al. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell 2006, 22:159-168.
-
(2006)
Mol Cell
, vol.22
, pp. 159-168
-
-
Sarbassov, D.D.1
Ali, S.M.2
Sengupta, S.3
-
55
-
-
34547636060
-
Correlation of survival with tumor histology, age and prognostic risk group for previously untreated patients with advanced renal cell carcinoma receiving temsirolimus or interferon alpha
-
[abstract 5033]
-
Dutcher J., Szczylik C., Tannir N., et al. Correlation of survival with tumor histology, age and prognostic risk group for previously untreated patients with advanced renal cell carcinoma receiving temsirolimus or interferon alpha. J Clin Oncol 2007, 25(Suppl. 18S). [abstract 5033].
-
(2007)
J Clin Oncol
, vol.25
, Issue.SUPPL. 18S
-
-
Dutcher, J.1
Szczylik, C.2
Tannir, N.3
-
56
-
-
48649107474
-
Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial
-
Motzer R.J., Escudier B., Oudard S., et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008, 372:449-456.
-
(2008)
Lancet
, vol.372
, pp. 449-456
-
-
Motzer, R.J.1
Escudier, B.2
Oudard, S.3
-
57
-
-
84896738853
-
Everolimus and temsirolimus associated pneumonitis in patients with metastatic renal cell cancer: a single-center experience
-
[abstract 401]
-
Cauley D.H., Atkinson B.J., Ng C.S., et al. Everolimus and temsirolimus associated pneumonitis in patients with metastatic renal cell cancer: a single-center experience. J Clin Oncol 2012, 30(Suppl. 5). [abstract 401].
-
(2012)
J Clin Oncol
, vol.30
, Issue.SUPPL. 5
-
-
Cauley, D.H.1
Atkinson, B.J.2
Ng, C.S.3
-
58
-
-
66649133114
-
A phase II study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic clear cell renal cell cancer
-
Amato R.J., Jac J., Giessinger S., et al. A phase II study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic clear cell renal cell cancer. Cancer 2009, 115:2438-2446.
-
(2009)
Cancer
, vol.115
, pp. 2438-2446
-
-
Amato, R.J.1
Jac, J.2
Giessinger, S.3
-
59
-
-
79952806004
-
Drug-related pneumonitis in patients with advanced renal cell carcinoma treated with temsirolimus
-
Maroto J.P., Hudes G., Dutcher J.P., et al. Drug-related pneumonitis in patients with advanced renal cell carcinoma treated with temsirolimus. J Clin Oncol 2011, 29:1750-1756.
-
(2011)
J Clin Oncol
, vol.29
, pp. 1750-1756
-
-
Maroto, J.P.1
Hudes, G.2
Dutcher, J.P.3
-
60
-
-
33750321673
-
A phase I and pharmacokinetic study of temsirolimus (CCI-779) administered intravenously daily for 5 days every 2 weeks to patients with advanced cancer
-
Hidalgo M., Buckner J.C., Erlichman C., et al. A phase I and pharmacokinetic study of temsirolimus (CCI-779) administered intravenously daily for 5 days every 2 weeks to patients with advanced cancer. Clin Cancer Res 2006, 12:5755-5763.
-
(2006)
Clin Cancer Res
, vol.12
, pp. 5755-5763
-
-
Hidalgo, M.1
Buckner, J.C.2
Erlichman, C.3
-
61
-
-
84862777361
-
Efficacy and safety of everolimus in elderly patients with metastatic renal cell carcinoma: an exploratory analysis of the outcomes of elderly patients in the RECORD-1 Trial
-
Porta C., Calvo E., Climent M.A., et al. Efficacy and safety of everolimus in elderly patients with metastatic renal cell carcinoma: an exploratory analysis of the outcomes of elderly patients in the RECORD-1 Trial. Eur Urol 2012, 61:826-833.
-
(2012)
Eur Urol
, vol.61
, pp. 826-833
-
-
Porta, C.1
Calvo, E.2
Climent, M.A.3
-
62
-
-
79851500081
-
Everolimus for advanced pancreatic neuroendocrine tumors
-
Yao J.C., Shah M.H., Ito T., et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 2011, 364:514-523.
-
(2011)
N Engl J Med
, vol.364
, pp. 514-523
-
-
Yao, J.C.1
Shah, M.H.2
Ito, T.3
-
63
-
-
84881547645
-
-
CHMP Assessment report for everolimus. Available from: [accessed 11.09.12].
-
CHMP Assessment report for everolimus. Available from: [accessed 11.09.12]. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/001038/WC500022817.pdf.
-
-
-
|